Financing success for two start-ups

Wednesday was a busy day for start-up Israeli science and technology firms as BrainStorm Cell Therapeutics, an adult stem cell development company, announced that it had entered into an agreement for a $5m. financing offer from ACCBT Corporation.

By YONI TEITZ
July 5, 2007 07:13

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Wednesday was a busy day for start-up Israeli science and technology firms as BrainStorm Cell Therapeutics, an adult stem cell development company, announced that it had entered into an agreement for a $5m. financing offer from ACCBT Corporation. Correlsense, a business transaction software company, completed a $1.5m. financing agreement with three Israeli investment companies. BrainStorm, based in Petah Tikva and New York, is currently researching stem cell treatments for Parkinson's disease, ALS (Lou Gehrig's disease) and multiple sclerosis, while Correlsense, based in Herzliya Pituah, enables businesses to better control and monitor computer-based transactions.

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS